CGBio, a company specializing in regenerative medicine, announced on December 17 that it had received the '20 Million Dollar Export Tower' award at the 62nd Trade Day ceremony. This award signifies that CGBio's unique technological competitiveness and global market expansion strategy in the regenerative medicine sector are now yielding tangible results in the global market. The company’s export performance and overseas business competitiveness have been officially recognized by the government.
In addition to this award, CGBio continues to strengthen its mid- to long-term global strategies, including a focused approach to advanced markets in North America and Europe, the global launch of a comprehensive regenerative medicine portfolio, the advancement of overseas production and logistics infrastructure, and the expansion of strategic partnerships and joint research initiatives.
Yu Hyunseung, CEO of CGBio, is taking a commemorative photo with the '20 Million Dollar Export Tower' award plaque. CGBio
Since its establishment in 2006, CGBio has developed a variety of regenerative medicine solutions, leading to a significant increase in export performance this year compared to the previous year. The company has consistently expanded the export share of its core product lines by securing new partnerships in Europe, the Middle East, Southeast Asia, and South America. This growth trajectory culminated in winning the '20 Million Dollar Export Tower' award. Over the past three years, export performance has steadily increased: 12.55 million dollars two years ago, 17.44 million dollars last year, and 21.78 million dollars this year, recording an average annual growth rate of over 31%.
The 'Export Tower' is an award hosted by the Korea International Trade Association and organized by the Ministry of Trade, Industry and Energy. CGBio achieved the honor of receiving the '20 Million Dollar Export Tower' this year as its export performance reached 20 million dollars. The key drivers of CGBio’s export growth have been the balanced global supply of various product lines, including bone substitutes, wound care products, and aesthetic products. These products are exported to numerous countries in Europe, North America, Asia, and the Middle East, securing stable demand across diverse regions.
From its early days, the company has focused on developing technologies that address clinical needs and has established a quality system that meets global standards. As a result, CGBio has become competitive even in overseas markets with stringent safety and efficacy requirements for medical devices. Additionally, the company has continuously advanced its overseas expansion strategies, including accelerating overseas clinical trials and certifications, strategically participating in global conferences and exhibitions, collaborating with influential local medical professionals (KOLs), operating global education programs, and expanding its network of subsidiaries and specialized partners. These factors further reinforce CGBio’s positive outlook for mid- to long-term export growth.
Yu Hyunseung, CEO of CGBio, stated, "Winning the '20 Million Dollar Export Tower' is a moment when CGBio’s journey of continuous innovation over the past several years has been recognized on the international stage. It is the result of our unwavering belief that our unique regenerative medicine technology can change the lives of patients worldwide, and the passion of every member who has worked toward this goal. Moving forward, CGBio will continue to prioritize patient recovery, pursue research and challenges to provide better treatment experiences, and actively expand to further promote the value of K-bio technology in the global market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
